Author pages are created from data sourced from our academic publisher partnerships and public sources.
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
- L. Luznik, P. O'donnell, +20 authors E. Fuchs
- Biology of blood and marrow transplantation…
- 1 June 2008
We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative… Expand
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
- R. Rother, S. Rollins, C. Mojcik, R. Brodsky, L. Bell
- Biology, Medicine
- Nature Biotechnology
- 1 November 2007
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal… Expand
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.
Allogeneic marrow transplantation can cure sickle cell disease; however, HLA-matched donors are difficult to find, and the toxicities of myeloablative conditioning are prohibitive for most adults… Expand
Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita.
- M. Armanios, Jiunn-liang Chen, +8 authors C. Greider
- Medicine, Biology
- Proceedings of the National Academy of Sciences…
- 1 November 2005
Dyskeratosis congenita is a rare inherited disorder characterized by abnormal skin manifestations. Morbidity and mortality from this disease is usually due to bone marrow failure, but idiopathic… Expand
Cyclophosphamide and cancer: golden anniversary
Cyclophosphamide remains one of the most successful and widely utilized antineoplastic drugs. Moreover, it is also a potent immunosuppressive agent and the most commonly used drug in blood and marrow… Expand
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations… Expand
Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders
- S. Soden, C. Saunders, +24 authors S. Kingsmore
- Medicine, Biology
- Science Translational Medicine
- 3 December 2014
Molecular diagnosis of pediatric neurodevelopmental disorders by genomic sequencing is frequently informative and cost-effective and can affect clinical care. The End of the Odyssey?… Expand
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
- P. Hillmen, N. Young, +17 authors L. Luzzatto
- The New England journal of medicine
- 21 September 2006
BACKGROUND We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with… Expand
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders. In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to thromboembolism (TE),… Expand
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, acquired disorder of blood cells caused by mutation of the phosphatidylinositol glycan class A (PIG‐A) gene. The disease often manifests… Expand